pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
Insulin Glargine
Approved · small molecule · Diabetes Mellitus, Type 2
Insulin Glargine for Diabetes Mellitus, Type 2 is a Approved program (small_molecule) at Sanofi Pasteur with 2 ClinicalTrials.gov record(s).
Internal code EXT_LANTU_C_02761
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Diabetes Mellitus, Type 2
- Status
- completed
- Trials
- 2